US EditionSTAT6: A Challenging Target Gains Traction Utilizing Degraders for Th2-Driven Disease
Summary by Drug Hunter
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
STAT6: A Challenging Target Gains Traction Utilizing Degraders for Th2-Driven Disease
STAT6, once deemed undruggable, is now being targeted through protein degradation. This article highlights recent developments including Kymera’s KT‑621, a cereblon-based STAT6 degrader, that entered Ph. 1 and has shown >95% knockdown of STAT6 as well as Th2 biomarker suppression. It also surfaces preclinical programs from Nurix and the University of Michigan. STAT6 degradation marks a shift in targeting transcription factors for immune and canc…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
